Observou-se um caso de resistência à eritropoetina recombinante humana causada por Ectasia Vascular Antral Gástrica em uma mulher de 40 anos de idade. Abstract. DAL MASO, Rosina Conceição Graçaplena et al. Sex hormones in women on dialysis. Rev. Assoc. Med. Bras. [online]. , vol, n.4, pp . 22 out. Observou-se um caso de resistência à eritropoetina recombinante humana causada por Ectasia Vascular Antral. Gástrica em uma mulher de.

Author: Vudotaur Brazuru
Country: Latvia
Language: English (Spanish)
Genre: History
Published (Last): 7 April 2005
Pages: 222
PDF File Size: 3.3 Mb
ePub File Size: 8.52 Mb
ISBN: 694-2-69840-841-8
Downloads: 46296
Price: Free* [*Free Regsitration Required]
Uploader: Fekree

For this proposition, we evaluated two distinct groups, one test group, with 77 patients who made use of rHuEPO for three weeks, and a second control group, with 38 patients who did not use this treatment, totaling people. Since iron rrcombinante is a limiting factor and its supplementation is usually necessary to ensure an adequate response to EPO, combination of different classes of agents can be an approach to equate.

We are doing follow-up with endoscopies and treatments with APC to control of bleeding in lesions that tend to recur that is a limitation to the treatment of anemia and resistance to rHuEPO in this patient. However, there is the possibility of promoting activation of other genes, like VEGF, as described with HIF stabilizers, further studies being needed.

Sign in to the Lens

Erythropoietin blocks tumour cells apoptosis and potentiates angiogenesis, with increased tumour growth, metastases and reduction of the radiotherapy response Interruption of hepcidin gene activation, by IL-6, has also been proposed Glycolytic enzymes induction demonstrates the role of HIF in the autonomous cellular adaptation to hypoxia, producing ATP by glycolysis, instead of oxidative phosphorylation. There was no Raynaud’s phenomenon. Thus, it can be administered every two weeks or every month, during the maintenance phase of treatment ABSTRACT About 30 years ago, the treatment of chronic renal disease eriyropoetina was revolutionized by the introduction of recombinant human erythropoietin, which reduced the need for blood transfusions.


There were no esophageal varices. Erythropoietin EPOformerly named haemopoietin is essential to erythropoiesis. J Natl Cancer Inst ;93 N Engl J Med ; Watermelon stomach – antral region of the stomach with dilated vessels with signs of active bleeding.

Clin J Am Soc Nephrol ;3 1: Furthermore, renal failure itself contributes to inflammation with an increase in advanced glycation end products AGEa reduction in plasma antioxidant activity and loss of antioxidants such as zinc, selenium and vitamins C and E. Chronic kidney disease is characterized by renal impairment of glomerular function, tubular and endocrine, slow, progressive and irreversible, with anemia as a major complication, whose intensity and prevalence are related to the stage of kidney disease and disability in production erythropoietin EPO.

Understanding and exploiting hepcidin as an indicator of anemia due to chronic kidney disease. Similarly, it may play an important role reducing CKD oxidative stress and vascular dysfunction. Services on Demand Journal.

However, based on experience reported in the literature for patients with GAVE undergoing therapy with APC appropriate monitoring is required. The decrease in production can be achieved by interfering in regulatory pathways.

Brain protection by erythropoietin: Some associated factors such as autoimmune disease, hemolysis, heart and liver disease were discarded on physical examination and complementary tests.

Treatments are usually required on at least two occasions separated by six to eight weeks. Manipulation of the hepcidin pathway for therapeutic purposes. Erythropoietin may act on the regulation of metabolism and obesity and has potential benefits in the treatment of neurologic diseases, mood symptoms and depression Fig. Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. The histologic findings are not necessary to confirm the diagnosis but can be helpful.


During fetal life, EPO is produced by the liver. Hepcidin neutralization by an antihepcidin monoclonal antibody, tested in a mouse model of inflammatory anaemia caused by Brucella abortus heatkilledovercame EPO resistance.

Regulação da produção da eritropoietina e perspectivas terapêuticas na anemia

Whereas that RDW C-reactive protein was 1. We observed a case of recombinant human erythropoietin resistance caused by Gastric Antral Vascular Ectasia in a year-old female with ESRD on hemodialysis. Another of the agents approved by FDA was peginesatide, in PRS anticalin is a lipocalin derivative that binds specifically to human hepcidin. End stage renal disease; Dialysis; Sex hormones; Women; Recombinant human erythropoietin. A large proportion of CKD patients develop anaemia over the course of their disease, which is a risk factor associated with worse prognosis, either as an independent recomginante factor or as a risk multiplier in patients with concomitant cardiovascular disease Am J Kidney Dis ;38 4: Other laboratory findings showed normal total bilirubin 0.

It has other non-erythropoietic biological functions, like mitogenesis and angiogenesis, in part via endothelin-1 induction.